Xospata (Gilteritinib)

Save 33% on Xospata from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manufacturer for Europe: Astellas Pharma Europe B.V. Sylviusweg 62 2333 BE Leiden The Netherlands

Information about Xospata (Gilteritinib)

Xospata is a targeted therapy used to treat acute myeloid leukemia (AML) in patients with a specific genetic mutation, called FLT3, which drives the growth of the leukemia cells. Gilteritinib, the active ingredient in Xospata, is a tyrosine kinase inhibitor that works by blocking the FLT3 receptor, which is found on the surface of some leukemia cells. By inhibiting this receptor, Xospata can help slow the growth of cancer cells and may improve survival in patients with AML.

Product Highlights

• Xospata is specifically approved for the treatment of adult patients with FLT3-mutated AML, particularly those who have relapsed or are refractory to prior chemotherapy or other treatments.
• This medication is particularly effective in patients whose AML has come back after treatment or has not responded to other therapies.

Key Ingredient

• Gilteritinib

Key Benefits

• Xospata is a targeted therapy that specifically blocks the FLT3 receptor, a mutation commonly found in AML. This selective inhibition helps to control the proliferation of cancer cells while minimizing damage to healthy cells.
• Clinical studies have shown that Xospata can significantly improve survival rates in patients with FLT3-mutated AML who have not responded to previous treatments or whose leukemia has relapsed.
• Xospata is taken as a tablet, offering convenience compared to intravenous therapies that may require hospital visits or infusions.
• Xospata may be used in combination with chemotherapy or other therapies as part of a broader treatment strategy for AML.

Direction of Use

• The recommended dose of Xospata is typically 120 mg once daily, taken orally with or without food. Your doctor may adjust the dosage based on your individual response to the medication or any side effects you experience.
• Xospata should be swallowed whole, and it should not be crushed or chewed. Take it at the same time each day to help remember.
• It is important to take Xospata regularly as prescribed to maintain its effectiveness. Missing doses or stopping treatment prematurely can affect the success of the therapy.
• While on Xospata, your doctor will monitor your blood counts, liver function, and overall progress. This helps assess how well the medication is working and to catch any side effects early.

Safety Concerns

• The most common side effects of Xospata include nausea, diarrhea, fatigue, and liver enzyme abnormalities. These are usually manageable, but patients should report them to their healthcare provider.
• Xospata can cause liver toxicity, so liver function should be monitored regularly. In some cases, dose adjustments may be needed to reduce the risk of liver damage.
• Xospata can cause a prolongation of the QT interval, which is a change in the electrical activity of the heart that can lead to serious heart rhythm problems. Patients should be monitored for heart problems while on this medication.
• As with many cancer treatments, Xospata can weaken the immune system, increasing the risk of infections. Patients should be vigilant for signs of infection and notify their doctor if symptoms occur.
• Xospata may increase the risk of bleeding, including serious bleeding events. Patients should be cautious and avoid activities that could cause injury or bleeding.
• Low levels of potassium, magnesium, or calcium can occur during treatment with Xospata, so these levels will be monitored regularly.

Avoid Xospata (Gilteritinib) If

• If you have a known allergy to gilteritinib or any of the other ingredients in Xospata, you should not take this medication.
• Xospata is metabolized by the liver, and it can cause liver toxicity. It should be avoided in patients with severe liver impairment or active liver disease.
• If you have a history of prolonged QT interval, or certain heart conditions, Xospata may not be suitable for you due to the potential for causing serious heart rhythm problems.
• Xospata should not be used during pregnancy, as it may harm the unborn baby. If you are pregnant or planning to become pregnant, you should discuss alternative treatments with your healthcare provider.
• It is not known if Xospata passes into breast milk. Women who are breastfeeding should consult their doctor before taking Xospata, as it may not be safe for the baby.
• Xospata may interact with other medications that affect liver enzymes (like CYP3A4 inhibitors). Your doctor should review your full list of medications to avoid any dangerous interactions.